NVNO

enVVeno Medical Corporation · NASDAQ

Sector Health Technology
Industry Medical Specialties
Website envveno.com
Employees(FY) 30
ISIN US29415J1060

Performance

+0.4%

1W

+4.83%

1M

-0.6%

3M

+12.13%

6M

-2.92%

YTD

+28.28%

1Y

Profile

enVVeno Medical Corporation, a clinical med-tech company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of chronic venous disease. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

Advanced Technical Analysis

Technical Analysis of NVNO 2024-05-10

Overview:

In analyzing the technical indicators for NVNO over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming trading days.

Trend An...

See more ...

Recent News & Updates

2024-05-08 11:54
NVNO Stock Earnings: enVVeno Medical Beats EPS for Q1 2024(Investorplace)
2024-05-08 04:15
enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update(Accesswire)
2024-04-23 18:15
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium(Accesswire)
2024-04-23 18:15
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium(Accesswire)
2024-04-15 21:00
New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024(Accesswire)
2024-04-08 20:45
enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer(Accesswire)
2024-03-14 21:00
enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity(Accesswire)
2024-03-05 19:40
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting(Accesswire)
2024-02-29 03:15
enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update(Accesswire)
2024-02-19 19:30
Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024(Accesswire)
2023-12-13 22:30
enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposium(Accesswire)
2023-11-15 19:45
enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium(Accesswire)
2023-10-25 20:05
enVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Update(Accesswire)
2023-10-17 22:00
JTC Team Announces Presenting Company Line Up for the Virtual Investor Ask the CEO Conference Being Held October 24-25, 2023(Accesswire)
2023-10-11 21:00
enVVeno Medical to Participate at the Virtual Investor Ask the CEO Conference(Accesswire)
2023-10-05 20:57
enVVeno Medical Achieves Full Enrollment for VenoValve U.S. Pivotal Trial(Accesswire)
2023-10-05 20:56
enVVeno Medical Announces New Expedited Development Plan for the enVVe(R) Transcatheter Based Replacement Venous Valve(Accesswire)
2023-10-05 20:55
enVVeno Medical Announces Private Placement of $28 Million(Accesswire)
2023-07-31 04:45
enVVeno Medical Reports Second Quarter 2023 Financial Results and Provides Corporate Update(Yahoo Finance)
2023-07-13 20:05
enVVeno Medical to Host Virtual KOL Event on July 18, 2023(Yahoo Finance)
2023-07-04 20:05
enVVeno Medical Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study and Announces Upcoming Investor and KOL Events(Yahoo Finance)
2023-04-30 20:00
enVVeno Medical Reports First Quarter 2023 Financial Results and Provides Corporate Update(Yahoo Finance)
2023-03-02 04:15
enVVeno Medical Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update(Yahoo Finance)
2023-02-07 20:00
enVVeno Medical to Present at Cowen's 43rd Annual Health Care Conference(Yahoo Finance)
2023-01-17 19:05
enVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and Chief Technology Officer(Yahoo Finance)
2023-01-11 00:00
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th(Yahoo Finance)
2022-11-16 23:00
Positive 3-Year VenoValve(R) First-in-Human Data Presented at 49th Annual VEITH Symposium on Vascular and Endovascular Issues(Yahoo Finance)
2022-11-06 19:45
enVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study(Yahoo Finance)
2022-10-27 04:05
enVVeno Medical Reports Third Quarter 2022 Financial Results and Provides Corporate Update(Yahoo Finance)
2022-09-21 20:05
enVVeno Medical to Present at the Ladenburg Thalmann 2022 Healthcare Conference(Yahoo Finance)

Page 1 of 2

previousnext